PD-1 inhibitors (e.g., nivolumab, pembrolizumab) and CTLA-4 inhibitors (e.g., ipilimumab) are already approved for advanced ccRCC (4). The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.